All Stories
Follow
Subscribe to Marseille-Kliniken AG

Marseille-Kliniken AG

euro adhoc: Marseille-Kliniken AG
quarterly or semiannual financial statement / - Above average increase in operating profit to EUR 5.8 mill. pursuant to DVFA - Turnover increases to EUR 104.9 mill. - Turnaround in Rehabilitation segment confirmed

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
08.02.2006
Berlin, 8th February 2006: The Marseille-Kliniken AG (Prime Standard,
ISIN DE 0007783003, MKA) has been able to increase its turnover in
the first half of the fiscal year 2005/06 by EUR 2.5 million to EUR
104.9 million (previous year EUR 102.4 million). The operating profit
per DVFA/SG (IFRS) was increased by EUR 0.6 million from EUR 5.2
million to now EUR 5.8 million. Thus the operating profit increased
disproportionately to the turnover growth by 11.5 per cent. According
to German GAAP, the profit after taxes (without DVFA adjustments)
increased by EUR 5.2 million to EUR 8.8 million. The earnings per
share pursuant to DVFA reached EUR 0.48 following EUR 0.43 in the
same period last year.
The increase in turnover and operating profit results entirely from
the core segment Nursing, compensating for the still loss-making
Rehabilitation division. In the period under review the
Marseille-Kliniken AG was able to increase the number of beds to a
total of 8,168 beds (+ 754 beds). 80% of the total bed capacity is
accounted for in the Nursing division. In the period under review the
Nursing segment achieved an increase in turnover of around EUR 3.5
million, with a total of EUR 78.9 million in comparison to EUR 75.4
million in the previous year. The earnings per DVFA/SG (IFRS)
achieved in Nursing were EUR 7.0 million (previous year EUR 6.9
million). Taking into account the two start-up facilities in Landshut
and Montabaur, the capacity utilization rate in Nursing could be
increased from 90.7% in the previous year to 91.9% today.
Correspondingly, the capacity utilization rate in the whole company
increased from 87.5% to 89.2%.
Due to the further capacity decrease in the segment, the turnover in
the Rehabilitation segment in the first six months of the fiscal year
2005/06 was EUR 1.7 million below the previous year’s value of EUR
26.1 million. The losses made by the division could be further
reduced. Pursuant to the DVFA/SG (IFRS) losses could be reduced by
EUR 0.5 million, from EUR -1.7 million in the previous year to EUR
-1.2 million this year. The capacity utilization rate also developed
positively, increasing in the service division Rehabilitation from
76.3% last year to 77.2% this year.
The management awaits a marked improvement in profits in the Nursing
segment in the second half of the year due to an expected occupancy
increase.
end of announcement                               euro adhoc 08.02.2006 08:00:00

Further inquiry note:

Marseille-Kliniken AG
Axel Hölzer
CEO
Alte Jakobstraße 79/80
10709 Berlin
Tel.: +49 30 / 246 32-400
Fax: +49 30 / 246 32-401
or
HILLERMANN CONSULTING
Christian Hillermann
Eppendorfer Baum 5
20249 Hamburg
Tel.: +49 40/416 258-90
Fax: +49 40/416 258-94

Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurter Wertpapierbörse / official dealing/prime standard
Börse Berlin-Bremen / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Hamburger Wertpapierbörse / official dealing

Original content of: Marseille-Kliniken AG, transmitted by news aktuell

More stories: Marseille-Kliniken AG
More stories: Marseille-Kliniken AG